Relevant nursing measures for the adverse reactions associated with chimeric antigen receptor T cells (CAR-T) immunotherapy: a systematic review of case reports†
By:
References
- Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011;11:855-873.10.1517/14712598.2011.57347621463133
- Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood). 2015;240:1087-1098.10.1177/153537021558493625956686
- Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.2183094010.1056/NEJMoa1103849
- Zhu Y, Tan Y, Ou R, et al. Anti-cd19 chimeric antigen receptor-modified T cells for b-cell malignancies: a systematic review of efficacy and safety in clinical trials. Eur J Haematol. 2016;96:389-396.2611535810.1111/ejh.12602
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507-1517.10.1056/NEJMoa140722225317870
- Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188-195.10.1182/blood-2014-05-55272924876563
- Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-1518.2352795810.1056/NEJMoa1215134
- Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: cars take the front seat for hematologic malignancies. Blood. 2014;123:2625-2635.2457850410.1182/blood-2013-11-492231
- Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived cd19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129-4139.10.1182/blood-2013-08-51941324055823
- Ke XY. Application progress of chimeric antigen receptor - T cell immunotherapy in hematological malignancies. Chin General Med. 2016;19:1361-1366 (in Chinese).
- Moga C, Guo B, Schopflocher D. Development of a Quality Appraisal Tool for Case Series Studies Using a Modified Delphi Technique. Vol. 25. Edmonton AB: Institute of Health Economics; 2012:1262-1268.
- Yu LL. Nursing care of 7 children with advanced malignant solid tumor treated with CAR-T cell combined with chemotherapy. Tianjin Nurs. 2017;25:528-529 (in Chinese).
- Zhang P, Dai JX, Zhou L. Nursing care of patients with relapsed and refractory hematological malignancies undergoing CART cell therapy. Med Inf. 2016;29:226-227 (in Chinese).
- Chen XL, Feng YM, Zeng YJ, et al. Exploration of integrated nursing care on CAR-T cell immunotherapy for refractory acute lymphocytic leukemia. Chin J Blood Transfusion. 2016;29:1104-1107 (in Chinese).
- Feng N, Du X, Zhang C, Hao J, Zeng L. Nursing care of patients with recurrent refractory acute lymphoblastic leukemia treated with chimeric antigen receptor. Chongqing Med. 2016;45:140-141 (in Chinese).
- Li LN, Wan Y. Nursing care of patients with B cell malignant tumor treated with chimeric antigen receptor modified T cell immunotherapy. Chin J Nurs. 2017;52:297-299 (in Chinese).
- Ding YG, Zhao W, Wu XY, Ma XL. Nursing experience of children with neuroblastoma developing adverse reaction after retransfusion of chimeric antigen receptor-transduced T-cells. Chin J Nurs. 2017;52:307-310 (in Chinese).
- Turtle CJ. Chimeric antigen receptor modified T cell therapy for B cell malignancies. Int J Hematol. 2014;99:132-140.10.1007/s12185-013-1490-x24338745
- Yamauchi K, Yang M, Hayashi K, et al. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res. 2008;68:516-520.1819954710.1158/0008-5472.CAN-07-3063
- Pan J, Yang JF, Deng BP, et al. High efficacy and safety of low-dose cd19-directed CAR-T cell therapy in 51 refractory or relapsed b acute lymphoblastic leukemia patients. Leukemia. 2017;31:2587-2593.10.1038/leu.2017.14528490811
- Gardner RA, Finney O, Annesley C, et al. Intent to treat leukemia remission by cd19car T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322-3331.
- Mol MM, Boeter GW, Verharen L, Kompanje EJ, Bakker J, Nijkamp MD. Patient- and family-centered care in the intensive care unit, a challenge in the daily practice of healthcare professionals. J Clin Nurs. 2016;26:3212-3223.
- Thuy NL, Clemenceau AL, Lebaron VT. Challenges encountered by Vietnamese nurses when caring for patients with cancer. Oncol Nurs Forum. 2017;44:147-151.28222082
- Morsch CM, Gonçalves LF, Barros E. Health-related quality of life among haemodialysis patients - relationship with clinical indicators, morbidity and mortality. J Clin Nurs. 2006;15:498-504.10.1111/j.1365-2702.2006.01349.x16553764
Language: English
Page range: 87 - 95
Submitted on: Oct 3, 2018
Accepted on: Dec 22, 2018
Published on: Jul 10, 2019
Published by: Shanxi Medical Periodical Press
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2019 Xu Zhang, Di Sun, Gui-Chun Jiang, published by Shanxi Medical Periodical Press
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.